Beam Therapeutics Inc.
BEAM evidence brief
What we can confirm
- BioSniper Score:
- 4.8 / 10
- Market Cap:
- $2.49B
What it means
What to watch
Prepared research question
What matters most for BEAM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BEAM
Beam Therapeutics Inc. (BEAM) is a publicly traded biotechnology company developing a proprietary base-editing platform for precision genetic medicines, with lead programs in sickle cell disease and alpha-1 antitrypsin deficiency advancing toward late-stage clinical and regulatory milestones.
Key risk: Pre-revenue stage
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$2.49B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for Beam Therapeutics Inc..
Beam Therapeutics Inc. (BEAM) is a publicly traded biotechnology company developing a proprietary base-editing platform for precision genetic medicines, with lead programs in sickle cell disease and alpha-1 antitrypsin deficiency advancing toward late-stage clinical and regulatory milestones.
- Cash and equivalents of $219.8M as of 2026-06-30 [sec].
- Total revenue of $0.5M and net income of -$122.7M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $1,067.4M and total debt of $100.0M as of 2026-06-30 [sec].
- Positive initial safety and efficacy data disclosed for BEAM-302 in alpha-1 antitrypsin deficiency, with additional positive results announced in March 2026 [sec · filed 2026-04-17].
- U.S. Biologics License Application (BLA) submission for risto-cel (formerly BEAM-101) expected as early as year-end 2026 [news · published 2026-01-12].
What works
- Beam has a strong cash position, ending 2025 with an estimated $1.25 billion in cash, cash equivalents and marketable securities, providing an extended operating runway [news · published 2026-01-12].
- The company has reached alignment with the U.S. FDA on a potential accelerated approval pathway for BEAM-302 in AATD based on biomarker endpoints [news · published 2026-01-12].
- Beam's lead hematology program, risto-cel, has published data in the New England Journal of Medicine and is on track for a BLA submission as early as year-end 2026 [news · published 2026-05-07].
What to weigh
- Beam reported a net loss of $122.7M for the period ending 2026-06-30, with operating expenses expected to increase due to clinical development and BLA readiness activities [sec_mda · as of 2026-08-04].
- The company's revenue remains minimal at $0.5M as of 2026-06-30, reflecting a pre-commercial stage with no approved products [sec].
- Beam faces potential dilution risks as it continues to fund operations through equity and debt, with total debt of $100.0M as of 2026-06-30 [sec].
From the filings
Quoted directly from source documents.
Positive initial safety and efficacy data for BEAM-302 in AATD
“We disclosed positive initial safety and efficacy data in the Phase 1/2 clinical trial of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency, with additional positive results from the trial announced in March 2026”
SEC filings · April 17, 2026
FDA alignment on accelerated approval pathway for BEAM-302
“Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints”
News · January 12, 2026
BLA submission for risto-cel expected as early as year-end 2026
“U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026”
News · January 12, 2026
Cash position at end of 2025
“Ended 2025 with Estimated $1.25 Billion in Cash, Cash Equivalents and Marketable Securities”
News · January 12, 2026
Catalyst timeline
- 2022-08-30 · Phase 2 start for BEAM-101 (risto-cel) in sickle cell disease — A Phase 1/2 study evaluating a single dose of autologous CD34+ base edited hematopoietic stem cells in patients with sickle cell disease and severe vaso-occlusive crises.
- 2024-06-19 · Phase 2 start for BEAM-302 in AATD — A Phase 1/2 dose-exploration and dose-expansion study to evaluate safety and efficacy in adult patients with AATD-associated lung and/or liver disease.
- 2024-12-06 · Phase 2 start for BEAM-301 in GSDIa — A Phase 1/2 dose-exploration study in patients with glycogen storage disease type Ia homozygous or compound heterozygous for the G6PC1 c.247C>T variant.
Risks & what to watch (3)›
Key risks
- Pre-revenue stage — Revenue is only $0.5M as of 2026-06-30, with no approved products generating sales [sec].
- Rising operating expenses — Operating expenses expected to increase due to clinical development and BLA readiness activities [sec_mda · as of 2026-08-04].
- Dependence on regulatory approvals — Key programs (risto-cel, BEAM-302) are not yet approved; BLA submission for risto-cel expected as early as year-end 2026 [news · published 2026-01-12].
What to watch
- Initiation of the global pivotal cohort for BEAM-302 in AATD, expected in the second half of 2026 [news · published 2026-05-07].
- U.S. BLA submission for risto-cel in sickle cell disease, expected as early as year-end 2026 [news · published 2026-01-12].
- Expansion of the liver-targeted genetic disease franchise, with a new program to be announced in the first half of 2026 [news · published 2026-01-12].
- Cash runway and dilution risk as the company funds operations through equity and debt, with $100.0M in total debt as of 2026-06-30 [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Beam Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Beam Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.30 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
249
Total value held
$2.50B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 12,452,199 | $296.7M |
| ark investment management llc | 12,133,433 | $289.1M |
| farallon capital management llc | 10,134,696 | $241.5M |
| blackrock, inc. | 8,487,569 | $202.3M |
| state street corp | 5,699,265 | $135.8M |
| vanguard portfolio management llc | 4,570,797 | $108.9M |
| arch venture management, llc | 4,540,132 | $108.2M |
| vanguard capital management llc | 4,377,374 | $104.3M |
| amova asset management americas, inc. | 3,825,585 | $91.2M |
| sumitomo mitsui trust group, inc. | 3,825,585 | $91.2M |
Showing top 10 of 249 institutional holders of Beam Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 31.5%
- Days to cover
- 9.7
- Shares short
- 20,936,705
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BEAM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Beam Therapeutics Inc.?
Beam Therapeutics Inc. (BEAM) is a publicly traded biotechnology company developing a proprietary base-editing platform for precision genetic medicines, with lead programs in sickle cell disease and alpha-1 antitrypsin deficiency advancing toward late-stage clinical and regulatory milestones.
Who is the CEO of Beam Therapeutics Inc.?
Mr. John M. Evans M.B.A. is the chief executive officer of Beam Therapeutics Inc. (BEAM).
Where is Beam Therapeutics Inc. headquartered?
Beam Therapeutics Inc. (BEAM) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Beam Therapeutics Inc. focus on?
Beam Therapeutics Inc. develops therapies across Rare Disease, Respiratory, Hematology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.